1. Home
  2. Live Updates
  3. துணை நிறுவனங்கள் பங்கு

துணை நிறுவனங்கள் பங்கு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from துணை நிறுவனங்கள் பங்கு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In துணை நிறுவனங்கள் பங்கு Today - Breaking & Trending Today

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Stevena Shallcross , Company Phase , Washington University School Of Medicine , Net Loss Attributable To Synthetic Biologics Inc , Washington University , Safety Monitoring Committee , Louis Washington University , American Company Guide The , Synthetic Biologics Inc , Clinical Development , Synthetic Biologics , Chief Executive Officer , Washington University School , Massachusetts General , Company Guide , Ended June , Synthetic Biologic , Private Securities Litigation Reform Act , Synthetic Biologic Annual Report , Tables Follow , Convertible Preferred , Subsidiaries Equity , Stockholder Equity , Consolidated Statements , Operating Costs ,

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Stevena Shallcross , Company Phase , Washington University School Of Medicine , Net Loss Attributable To Synthetic Biologics Inc , Washington University , Safety Monitoring Committee , Louis Washington University , American Company Guide The , Synthetic Biologics Inc , Clinical Development , Synthetic Biologics , Chief Executive Officer , Washington University School , Massachusetts General , Company Guide , Ended June , Synthetic Biologic , Private Securities Litigation Reform Act , Synthetic Biologic Annual Report , Tables Follow , Convertible Preferred , Subsidiaries Equity , Stockholder Equity , Consolidated Statements , Operating Costs ,

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results


Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results
Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD
Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
Reports $76.9 Million of Cash on Hand to Fund Clinical Programs Through Proof-of-Concept and Extend Operations into 2023
Conference Call Today at 4:30 p.m. (ET)
News provided by
Share this article
Share this article
ROCKVILLE, Md., May 5, 2021 /PRNewswire/  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2021. ....

United States , Stevena Shallcross , Company Phase , Washington University School Of Medicine , Net Loss Attributable To Synthetic Biologics Inc , Washington University , Safety Monitoring Committee , Louis Washington University , Synthetic Biologics Inc , Clinical Development , Synthetic Biologics , Chief Executive Officer , Washington University School , Massachusetts General Hospital , Ended March , Synthetic Biologic , Private Securities Litigation Reform Act , Synthetic Biologic Annual Report , Tables Follow , Convertible Preferred , Subsidiaries Equity , Stockholder Equity , Consolidated Statements , Operating Costs , Loss Attributable , Preferred Stock ,

Synthetic Biologics Reports 20 - GuruFocus.com


Confirm
Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD
Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
Reports $76.9 Million of Cash on Hand to Fund Clinical Programs Through Proof-of-Concept and Extend Operations into 2023
Conference Call Today at 4:30 p.m. (ET)
PR Newswire
ROCKVILLE, Md., May 5, 2021
ROCKVILLE, Md., May 5, 2021 /PRNewswire/  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2021. ....

United States , Stevena Shallcross , Company Phase , Washington University School Of Medicine , Net Loss Attributable To Synthetic Biologics Inc , Washington University , Safety Monitoring Committee , Louis Washington University , Synthetic Biologics Inc , Prnewswire Synthetic Biologics Inc , Clinical Development , Chief Executive Officer , Washington University School , Massachusetts General Hospital , Ended March , Synthetic Biologics , Synthetic Biologic , Private Securities Litigation Reform Act , Synthetic Biologic Annual Report , Tables Follow , Convertible Preferred , Subsidiaries Equity , Stockholder Equity , Consolidated Statements , Operating Costs , Loss Attributable ,